JP2015512948A - ハロフェナートまたはハロフェン酸および抗炎症剤を用いる痛風に罹っている患者の高尿酸血症の治療方法 - Google Patents

ハロフェナートまたはハロフェン酸および抗炎症剤を用いる痛風に罹っている患者の高尿酸血症の治療方法 Download PDF

Info

Publication number
JP2015512948A
JP2015512948A JP2015505961A JP2015505961A JP2015512948A JP 2015512948 A JP2015512948 A JP 2015512948A JP 2015505961 A JP2015505961 A JP 2015505961A JP 2015505961 A JP2015505961 A JP 2015505961A JP 2015512948 A JP2015512948 A JP 2015512948A
Authority
JP
Japan
Prior art keywords
day
colchicine
therapeutic agent
uric acid
gout
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015505961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512948A5 (enExample
Inventor
ゴパール・チャンドラ・サハ
ブライアン・エドワード・ラバン
ブライアン・ケイ・ロバーツ
チャールズ・エイ・マックワーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CymaBay Therapeutics Inc filed Critical CymaBay Therapeutics Inc
Publication of JP2015512948A publication Critical patent/JP2015512948A/ja
Publication of JP2015512948A5 publication Critical patent/JP2015512948A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015505961A 2012-04-13 2013-04-12 ハロフェナートまたはハロフェン酸および抗炎症剤を用いる痛風に罹っている患者の高尿酸血症の治療方法 Pending JP2015512948A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624186P 2012-04-13 2012-04-13
US61/624,186 2012-04-13
PCT/US2013/036474 WO2013155478A1 (en) 2012-04-13 2013-04-12 Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent

Publications (2)

Publication Number Publication Date
JP2015512948A true JP2015512948A (ja) 2015-04-30
JP2015512948A5 JP2015512948A5 (enExample) 2016-06-02

Family

ID=49325641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015505961A Pending JP2015512948A (ja) 2012-04-13 2013-04-12 ハロフェナートまたはハロフェン酸および抗炎症剤を用いる痛風に罹っている患者の高尿酸血症の治療方法

Country Status (15)

Country Link
US (1) US20130274331A1 (enExample)
EP (1) EP2836209A4 (enExample)
JP (1) JP2015512948A (enExample)
KR (1) KR20150002799A (enExample)
CN (1) CN104602686A (enExample)
AU (1) AU2013245675B2 (enExample)
CA (1) CA2870014A1 (enExample)
CL (1) CL2014002728A1 (enExample)
EA (1) EA028495B1 (enExample)
HK (1) HK1204913A1 (enExample)
IL (1) IL235154A0 (enExample)
MX (1) MX2014012376A (enExample)
PH (1) PH12014502282A1 (enExample)
SG (1) SG11201406495UA (enExample)
WO (1) WO2013155478A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023035118A (ja) * 2021-08-31 2023-03-13 国立大学法人広島大学 体液サンプリング容器

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503440UA (en) 2012-11-02 2015-06-29 Heart Care Western Australia Pty Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
BR112015026418B1 (pt) 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501383A (ja) * 1999-06-04 2003-01-14 メタボレックス， インコーポレイテッド インスリン抵抗性、２型糖尿病、高脂血症および高尿酸血症の処置のための、（−）（３−トリハロメチルフェノキシ）（４−ハロフェニル）酢酸誘導体の使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US8829058B2 (en) * 2008-03-13 2014-09-09 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
CA2718062A1 (en) * 2008-03-14 2009-09-17 Intelliherb, Llc Licorice lollipop that inhibits dental caries formation
US20100137235A1 (en) * 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
MX357510B (es) * 2011-11-04 2018-07-12 Cymabay Therapeutics Inc Metodos para tratar ataques de gota.
BR112014010693A2 (pt) * 2011-11-04 2020-11-10 Cymabay Therapeutics, Inc. uso de um composto para a preparação de uma composição farmacêutica para o tratamento de gota em subpopulações de pacientes
WO2013066349A1 (en) * 2011-11-04 2013-05-10 Metabolex, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
US9060987B2 (en) * 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501383A (ja) * 1999-06-04 2003-01-14 メタボレックス， インコーポレイテッド インスリン抵抗性、２型糖尿病、高脂血症および高尿酸血症の処置のための、（−）（３−トリハロメチルフェノキシ）（４−ハロフェニル）酢酸誘導体の使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS AND RHEUMATISM, vol. 18, no. 6, JPN6016049927, 1975, pages 859 - 862, ISSN: 0003469951 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023035118A (ja) * 2021-08-31 2023-03-13 国立大学法人広島大学 体液サンプリング容器
JP7850976B2 (ja) 2021-08-31 2026-04-24 国立大学法人広島大学 体液サンプリング容器

Also Published As

Publication number Publication date
CN104602686A (zh) 2015-05-06
AU2013245675A1 (en) 2014-10-30
EA201491870A1 (ru) 2015-03-31
EA028495B1 (ru) 2017-11-30
WO2013155478A1 (en) 2013-10-17
US20130274331A1 (en) 2013-10-17
PH12014502282A1 (en) 2014-12-15
EP2836209A4 (en) 2015-11-25
IL235154A0 (en) 2014-12-31
KR20150002799A (ko) 2015-01-07
SG11201406495UA (en) 2014-11-27
AU2013245675B2 (en) 2017-02-09
CA2870014A1 (en) 2013-10-17
HK1204913A1 (en) 2015-12-11
MX2014012376A (es) 2015-06-05
CL2014002728A1 (es) 2015-06-19
EP2836209A1 (en) 2015-02-18

Similar Documents

Publication Publication Date Title
JP6008974B2 (ja) 痛風発赤の治療方法
US10137112B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
JP6202633B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
AU2013245675B2 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
JP6368756B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
US20210161908A1 (en) Preventative and therapeutic agents for sarcopenia
US20130302305A1 (en) Methods for Treating Gout in Patients Subpopulations
JP6192142B2 (ja) 痛風発赤の治療方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170905